Sung-soo H. Yoon
Advanced in Graft Versus Host Disease (GvHD)

Sung-soo H. Yoon

Seoul, KR 
Advanced in Graft Versus Host Disease (GvHD)
Seoul, KR 
OverviewLocationsClinical Research

Overview

Sung-soo Yoon practices in Seoul, Republic of Korea. Mr. Yoon is rated as an Advanced expert by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 394 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles in the study of Graft Versus Host Disease (GvHD).

Gender
Male

Locations

Seoul, Republic of Korea
Other Locations
Songnam, Republic of Korea
Gwangju, Republic of Korea
Yangsan, Republic of Korea
Ulsan, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
Phase II Study of Glofitamab, Poseltinib and Lenalidomide in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Phase II Study of Glofitamab, Poseltinib and Lenalidomide in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)
A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)
Enrollment Status: Completed
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 1
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Enrollment Status: Unknown
Publish Date: July 24, 2018
Intervention Type: Drug
Study Drugs: Rituximab, Modified VPDL
Study Phase: Phase 2
View 4 Less Clinical Trials

394 Total Publications

Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.
Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.
Journal: British journal of haematology
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yoon's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 17 Advanced Conditions
View All 62 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile